Trial · NCT00720109
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy | Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy) | 79.8 | 90% Confidence Interval 71.1 to 88.5 | Percent probability | |
| Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy | Standard-risk | 83.2 | 90% Confidence Interval 74.1 to 92.2 | Percent probability | |
| Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy | High-risk | 66.7 | 90% Confidence Interval 40.9 to 92.5 | Percent probability | |
| Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events | Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy) | 1 | Pts with DLTs | ||
| Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy | Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy) | 40.7 | 90% Confidence Interval 30.8 to 51.4 | Percentage of participants | |
| Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy | Standard-risk | 29.2 | 90% Confidence Interval 19.7 to 40.9 | Percentage of participants | |
| Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy | High-risk | 100.0 | 90% Confidence Interval 73.1 to 100.0 | Percentage of participants | |
| Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation | Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy) | 10.5 | 90% Confidence Interval 5.3 to 19.3 | Percentage of participants | |
| Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation | Standard-risk | 0 | 90% Confidence Interval 0.0 to 6.4 | Percentage of participants | |
| Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation | High-risk | 66.7 | 90% Confidence Interval 39.6 to 96.1 | Percentage of participants | |
| Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib) | Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy) | 79.8 | 90% Confidence Interval 71.1 to 88.5 | percentage of patients | |
| Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib) | Standard-risk | 83.2 | 90% Confidence Interval 74.1 to 92.2 | percentage of patients | |
| Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib) | High-risk | 66.7 | 90% Confidence Interval 40.9 to 92.5 | percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00720109/results